Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Summary

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone is a clinical trial^[1].

Key Facts

• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone is in the country of Austria^[2].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone is in the country of Greece^[3].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone is in the country of Hungary^[4].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone is in the country of Japan^[5].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone is in the country of Portugal^[6].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone is in the country of Romania^[7].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's instance of is recorded as clinical trial^[8].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's start time is recorded as +2008-03-31T00:00:00Z^[9].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's end time is recorded as +2009-06-30T00:00:00Z^[10].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's sponsor is recorded as Boehringer Ingelheim^[11].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's main subject is recorded as diabetes^[12].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's number of participants is recorded as {'unit': '1', 'amount': '+389'}^[13].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's title is recorded as A Randomised, Double-blind, Placebo Controlled, Parallel Group 24 Week Study to Assess the Efficacy and Safety of BI 1356 (5 mg) in Combination With 30 mg Pioglitazone (Both Administered Orally Once Daily), Compared to 30 mg Pioglitazone Plus Placebo in Drug Naive or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control.^[14].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[15].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's ClinicalTrials.gov ID is recorded as NCT00641043^[16].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+80'}^[17].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's research intervention is recorded as (RS)-pioglitazone^[18].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's research intervention is recorded as linagliptin^[19].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's clinical trial phase is recorded as phase III clinical trial^[20].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's research subject recruitment status is recorded as completed^[21].
• Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone's study type is recorded as interventional study^[22].